Plasmablastic Lymphoma in the Testis and Duodenum: A Case Report and Literature Review

Jennifer Y. Sheng, Daniel A. Baik, Lilly Yi, Nasheed Hossain, David Essex

Abstract

Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of non-Hodgkin’s lymphoma (NHL) associated with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV). There are over 300 reported cases of PBL, of which over 120 are reported in HIV-positive patients. Of HIV-negative patients, patients were either immunocompetent or immunosuppressed transplant recipients. Initial reports highlighted cases arising in the oral cavity of HIV patients and this remains the most prevalent site of disease. However, other sites such as the gastrointestinal tract and skin are the next most common sites. Only three cases have involved the testes, a sanctuary site. Of gastrointestinal sites, there are only a handful of cases with gastric involvement. In the pre-human antiretroviral therapy (HAART) era, median overall survival was dismal. However, prognosis has improved since their advent. There is no significant difference in the survival of HIV-positive and HIV-negative PBL patients. It should be emphasized that due to the scarcity of cases, there are no established standards of care or prospective therapeutic trials for the management and treatment of PBL. Chemotherapy remains the standard approach, though selecting a regimen is still controversial and while response has been good, overall survival remains poor. Since 1995, autologous hematopoietic cell transplantation (AHCT) has been the standard of care for relapsed chemosensitive HIV-negative NHL. In the era of HAART, this has become feasible for HIV patients. A few studies have suggested that use of AHCT in the first line setting and relapsed or refractory disease may confer better outcomes. Herein we describe a unique case of involvement in the testis and duodenum, and there are no previous reports of a patient presenting with both gastrointestinal and urogenital involvement.

Keywords: Plasmablastic lymphoma; Non-Hodgkin’s lymphoma; HIV

Introduction

Plasmablastic lymphoma (PBL) is a rare and highly aggressive subtype of non-Hodgkin’s lymphoma (NHL) associated with human immunodeficiency virus (HIV) and Epstein-Barr virus (EBV). In the 2008 World Health Organization (WHO) classification, it is a distinct entity of B-cell lymphoma with “diffuse proliferation of large neoplastic cells most of which resemble B cell immunoblasts, but in which all tumor cells have a plasma cell immunophenotype” [1]. It was originally described in the oral cavity of patients with acquired immunodeficiency syndrome (AIDS) [2] but is also present in post-transplant patients [3, 4], elderly [5], immunosuppressed [6, 7] and immunocompetent patients [8, 9]. PBL accounts for about 2.6% of all AIDS-related lymphomas [10].

In the era before human antiretroviral therapy (HAART), median overall survival (OS) was 2.1 months [11]. However, prognosis has markedly improved since their advent [12-15]. There are over 300 reported cases of PBL, of which over 120 are present in HIV-positive patients. There is no significant difference in survival of HIV-positive and HIV-negative PBL patients. Overall median survival is 8 months but varies considerably (range 0 to 105 months). Overall, 62% of deceased patients died of lymphoma, while 12% died of sepsis and 6% multiorgan failure [16].

Due to the scarcity of cases, there are no established standards of care and no prospective therapeutic trials that have been done in patients with PBL.

Case Report

A 46-year-old Caucasian HIV-positive man, never on HAART, presented with 2 weeks of decreased PO intake, weight loss, increasing fatigue, and a swollen left testicle. On physical exam, he was cachectic with a BMI of 18.4, febrile, hypotensive, had oral thrush and a firm, non-tender, left testicular mass with inguinal lymphadenopathy. His fecal occult blood testing was positive. Complete blood count revealed critically
severe microcytic anemia and thrombocytosis (MCV 66 fl, hemoglobin 4.6 g/dL, platelets 570 × 10^3/µL). Iron study labs suggested a multifactorial etiology for his anemia (Fe 16 µg/dL, TIBC 155 µg/dL, ferritin 89 ng/mL, transferrin 110 mg/dL). The patient was found to be hyponatremic (Na 131) and hypoalbuminemic (albumin 1.7 g/dL, prealbumin 4.4 mg/dL). His LDH level was markedly elevated (LDH 998 U/L). Blood cultures were negative.

Ultrasound showed a 3-cm hypervascular solid left testicular mass and multiple retroperitoneal masses of varying size. CT revealed a large, ulcerated, distal gastric mass, peritoneal carcinomatosis in the form of macroscopic peritoneal deposits and small volume ascites, and re-identified the known left intratesticular tumor, which measured 2.8 × 2.0 cm. Evidence of an opportunistic infection and lack of HAART prompted further evaluation of his HIV status. He was found to have a CD4 count of 78/µL and viral load of 600,000 copies/mL. After consulting infectious disease, HAART, consisting of ritonavir, emtricitabine-tenofovir, and darunavir was initiated. Given a CD4 < 200, sulfamethoxazole-trimethoprim prophylaxis was started. HIV genotyping did not show any mutations, allowing the established HAART regimen to continue.

Upon admission, the patient was febrile without an established source of infection. Blood and urine cultures were negative. Chest X-ray on day 5 showed a right-sided pleural effusion with surrounding edema; vancomycin was started. A non-contrast CT was consistent with the chest X-ray and showed no evidence for pneumonia. The fevers resolved by day 11 and he was cleared for the OR.

An upper gastrointestinal (GI) endoscopy showed a large, fungating, ulcerated, circumferential mass in the body and antrum, partially obstructing the duodenum, which was biopsied. The pathology report revealed PBL and H. pylori (Fig. 1-3).

Quadruple therapy was started for a 14-day course. Per recommendation of hematology oncology, IR-guided bone marrow biopsy and retroperitoneal biopsy were performed to stage the cancer. The patient had mild coagulopathy (PT 15.1 s, INR 1.3, PTT 40.4 s). Vitamin K was administered and workup revealed a minimal factor deficiency (factor 2: 0.58 U/mL, factor 10: 0.74 U/mL) which was attributed to cachexia and poor nutrition. The retroperitoneal biopsy was consistent with previously found gastric PBL, but the bone marrow biopsy was negative for lymphomatous involvement.

The testicular mass continued to enlarge over several days, resulting in tenderness and penile edema. The patient was amenable to a radical left orchiectomy. The pathology result of the testicular mass was consistent with PBL. Given the metastatic nature of his cancer and the involvement of a sanctuary site, hematology oncology recommended prophylactic intrathecal chemotherapy prior to the initiation of rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone (R-CHOP). The patient received 12 mg intrathecal methotrexate with prednisone, which was well tolerated. He received his first course of R-CHOP during his admission. Follow-up with
the HIV clinic and hematology was established prior to discharge.

Over the course of 6 months, the patient received six cycles of R-CHOP and prophylactic intrathecal methotrexate. Post-treatment PET/CT reveals marked residual PET-avidity in the region of the duodenum, highly concerning for persistence of lymphomatous disease at the site. Patient was referred to GI for direct visualization and biopsy of the hypermetabolic duodenal region. If this confirms residual disease, we will further discuss the optimal salvage regimen at that time.

**Discussion**

Within 5 years of PBL first being described in 1992, the first case series of PBL in the oral cavity of HIV patients was published by Delecluse et al [2]. However, none of the patients in the case series were receiving HAART and the current widespread utilization of HAART therapy may be contributing to the current wide distribution of sites of disease in cases of PBL. In addition there is the possibility that increased clinical suspicion has resulted in more PBL cases being diagnosed that otherwise would have gone undiagnosed or misdiagnosed [17].

In the two largest meta-analyses of over 200 reported cases of PBL, over 120 cases (50% and 69% respectively) were patients whom were HIV-positive [16, 18]. Of HIV-negative patients, 70% were immunocompetent and 28% were transplant recipients. The mean age of onset was 40 years and male/female ratio was 4.5:1. The primary sites were nodal (10 cases) and extranodal (117 cases) with majority of cases in the oral cavity (57 of 117), GI tract (21 of 117) and skin (13 of 117). Only three cases involved the urogenital tract, a sanctuary site [16, 19]. Of GI sites, there are six cases with stomach involvement (43%) [20]. Multiple organ involvement has also been noted [18, 21, 22]. PBL presents in advanced clinical stage, which is Ann Arbor Stage 3 or 4 [13, 16, 23]. There are no reports of a patient presenting with both a GI and a urogenital mass.

The pathogenesis of PBL is poorly understood but may be due to degree and duration of immunodeficiency, chronic antigenic stimulation or unresolved inflammatory state, EBV or gene rearrangement [24]. PBL is characterized by monomorphic cellular proliferation of round or oval cells with centrally or eccentrically placed nuclei and abundant eosinophilic cytoplasm in a diffuse growth pattern. Apoptotic bodies and mitotic figures and macrophages can lead to a starry sky appearance [2].

PBL has the immunophenotype of a terminally differentiated B cell. Classic B cell markers, such as CD20, CD79a, PAX-5 and CD45, are lost. Plasma cell markers, such as CD38, CD138 and myeloma oncogene-1 (MUM1/IRF4) are expressed [23, 25, 26]. There is also a high proliferation rate reflected by Ki67 expression > 80%. Despite having an immunophenotype that resembles plasma cells, PBL has a genomic profile closer to diffuse large B cell lymphoma (DLBCL) [27, 28].

In patients with HIV-associated PBL, > 75% are EBV-positive [13, 16]. This observation may be explained by the hypothesis that EBV-positive lymphoma cells gradually lose...
EBV while accumulating genetic mutations resulting in a more aggressive phenotype or that it can trigger more effective immune responses. EBV-positive PBLs have a significantly better outcome compared to their EBV-negative counterparts. In the HIV+ population, EBV-positive cases have a reported mean survival of 13 months as opposed to 9 months in EBV-negative cases. In a review of all cases of PBL, EBV-positive survival was 14 months as opposed to 10 months in EBV-negative [16]. Patients with PBL who are not treated with chemotherapy have a median survival of 3 months [13]. Even with treatment, the most common cause of death in these patients is progression of their lymphoma. Retrospective studies demonstrate median progression free survival (PFS) and OS are 6 and 11 months, respectively [16, 17].

Prognostic factors associated with longer survival are early clinical stage and obtaining a complete response with chemotherapy. Use of HAART shows a trend towards statistical significance for better survival, potentially due to restoration of immune surveillance [5, 29, 30]. CD45 (partially expressed in 37% of cases) was associated with better outcomes, suggesting that the absence of CD45 may have prognostic implications [16].

Factors associated with worse outcomes are: age > 60 years, advanced stage at diagnosis, bone marrow involvement and lack of response with treatment [13]. Extraoral presentation sites tend to have decreased OS as compared to those with oral presentation. However, this observation was in a study with a small number of cases and requires validation with a larger group [31]. In addition, PBL with alteration of C-myc (57%) is associated with worse outcomes [16, 28, 32, 33].

The choice of initial chemotherapy regimen remains controversial and while response to a variety of regimens has been good, OS remains poor. The National Comprehensive Cancer Network (NCCN) guidelines indicate that “standard CHOP is not adequate therapy” and suggest treatment with intensified regimens, such as etoposide, prednisone, vincristine, doxorubicin, cyclophosphamide (EPOCH), hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with methotrexate and cytarabine (HyperCVAD) or cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with methotrexate and cytarabine (HyperCVAD) or cyclophosphamide, vincristine, doxorubicin, methotrexate/ifosfamide, etoposide, cytarabine (CODOX-M/IVAC) [30]. Some studies have shown improved OS with EPOCH [34-36]. It should be emphasized that although the complete response rate is over 60%, many case series and reviews show no benefits with regards to PFS or OS when comparing treatment with CHOP versus more intensified regimens such as EPOCH [17, 29].

Intrathecal prophylaxis is a mandatory part of systemic treatment as HIV-associated PBLs are at risk for leptomeningeal disease. Either methotrexate or cytarabine can be used [37, 38]. Several case reports describe bortezomib, a proteasome inhibitor with activity in multiple myeloma, as an active agent in relapsed PBL [39-42].

The outcome for relapsed PBL is dismal. A few studies have suggested that use of autologous hematopoietic cell transplantation (AHCT) in the first line setting and relapsed or refractory disease may confer better outcomes [5, 40, 43]. Since 1995, AHCT has been the standard of care for relapsed chemosensitive HIV-negative NHL [44]. In the era of HAART, this has become feasible for HIV patients [45].

In the literature, there are 25 patients with HIV and relapsed PBL who received AHCT [12, 43]. In three patients, 81% achieved PFS at 2 years [45-47]. Another study of four patients had 56.5% PFS at 3 years [4]. Another two patients treated with AHCT after induction with CHOP resulted in complete response at 83 months while the other progressed and died 4 months after AHCT [12]. Other studies have shown similar outcomes [48]. However, up to 60% of patients with relapsed or refractory lymphoma will progress before reaching AHCT [43, 49, 50].

Allogeneic hematopoietic cell transplantation (AlloHCT) had limited success due to significant exposure to opportunistic infection, high incidence of concomitant infections and complex drug-drug interactions [43]. In 2009, an HIV-positive man with PBL was noted to be alive over 2 years after AlloHCT [51]. Since there are still limited studies in this area, more is needed before further evaluation.

Conclusions

PBL is a rare disease with around 120 cases in the HIV population. While common sites are the GI tract and skin, we describe the only case of involvement in both the duodenum and testis. Although our patient has received chemotherapy for six cycles, he appears to have persistent disease. OS is minimally improved for these patients despite the advent of HAART and chemotherapy. While salvage chemotherapy could be offered in refractory setting, the options are limited and this patient’s survival appears poor. In the era of HAART, use of AHCT in the first line setting and relapsed or refractory disease may confer better outcomes. Further study of AHCT, established standards of care and prospective therapeutic trials are warranted in this population.

Abbreviations


References

1. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational re-

Articles © The authors   |   Journal compilation © J Hematol and Elmer Press Inc™   |   www.jh.elmerpress.com 199
28. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of
plasmablastic features. Mod Pathol. 2010;23(7):991-999.


44. Forman SJ. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010;16(9):1302-1308.


